Skip to main content
. Author manuscript; available in PMC: 2012 Oct 28.
Published in final edited form as: Cell. 2011 Oct 28;147(3):554–564. doi: 10.1016/j.cell.2011.09.035

Figure 3. EphA7 opposes tumor development in a murine model of FL.

Figure 3

A, A mosaic model of FL based on vavPBcl2 transgenic mice; B, Tumor latencies for animals receiving vavPBcl2 transgenic HSCs transduced with empty vector (black, n = 11), or shRNAs against EphA7 (red, n = 18) and p53 (green, n = 9) or over expressing c-Myc (blue, n = 7). C, Immunoblot on FACS purified vavPBcl2 lymphoma cells expressing vector or an shRNA against EphA7 and probed as indicated. D, Microscopic pathology and immunohistochemistry of vavPBcl2 lymphomas expressing the indicated constructs, red arrows indicate infiltrating tumor cells. See also Figure S3.